Analysis of Efficiency Of KDT-OAT and Removal Preparations on The Recovery of Pulmonary Tuberculosis


  • Kristin Berlianta Duha University of Prima Indonesia
  • Sri Lestari Ramadhani Nasution Magister Public Health, Faculty of Medicine, University of Prima Indonesia
  • Ermi Girsang Magister Public Health, Faculty of Medicine, University of Prima Indonesia
  • Tan Suyono Magister Public Health, Faculty of Medicine, University of Prima Indonesia



Background: Tuberculosis is one of the 10 most common causes of death and is the single most common cause of infection and causes illness every year in millions of people. The etiology of tuberculosis is the bacteria Mycobacterium tuberculosis and Mycobacterium bovis. These germs have a size of 0.5-4 microns x 0.3-0.6 microns with thin rods, straight or slightly bent, granular or have no sheath, but have a thick outer layer consisting of lipoids (especially mycolic acid). Based on data from the Riset Kesehatan Dasar in 2018 conducted by the Kementerian Kesehatan RI, the prevalence rate of pulmonary TB by doctors in Indonesia in 2018 was the same as in 2013 which was 0.4%. Based on the OAT guidelines used in Indonesia, there are two OAT drug preparations, namely OAT-KDT or (FDC) and the Kombipak package. Comparison of the efficacy of this drug in curing pulmonary TB also varies. Objective: To determine the efficacy of KDT-OAT and removal preparations on the cure rate of pulmonary TB. Methods: This type of research is a retrospective cohort study, which is a time-period approach. This study was conducted in October-November 2020. Results: There was no significant difference in treatment outcomes in pulmonary TB patients who received OAT-KDT or OAT-release preparations.


Adane, A. et al. (2020) ‘Prevalence and Associated Factors of Tuberculosis among Adult Household Contacts of Smear Positive Pulmonary Tuberculosis Patients Treated in Public Health Facilities of Haramaya District, Oromia Region, Eastern Ethiopia’, Tuberculosis Research and Treatment, pp. 1–7. doi: 10.1155/2020/6738532.

Al-Shaer, M. H. et al. (2017) ‘Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar’, BMC Infectious Diseases, 17(118), pp. 1–6. doi: 10.1186/s12879-017-2231-1.

Albanna, A. S. et al. (2013) ‘Fixed-dose combination antituberculosis therapy: A systematic review and meta-analysis’, European Respiratory Journal, 42(3), pp. 721–732. doi: 10.1183/09031936.00180612.

Ayed, H. Ben et al. (2018) ‘Safety and Disease Evolution of Fixed-Dose Combination of Antitubercular Treatment Compared to Separate-Drugs Preparation in Extra-Pulmonary Tuberculosis’, Current Pharmacology Reports, 4(6), pp. 415–421. doi: 10.1007/s40495-018-0154-1.

Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI (2013) Riset Kesehatan Dasar 2013, Kementrian Kesehatan Republik Indonesia. doi: 1 Desember 2013.

Bahar, A. and Amin, Z. (2017) ‘Pengobatan Tuberkulosis Mutakhir’, in Setiati, S. et al. (eds) Buku Ajar Ilmu Penyakit Dalam Jilid I Edisi VI. Jakarta: Interna Publishing.

Carroll, C. K. et al. (2016) Medical Microbiology 27th Edition. New York: McGraw-Hill Education.

Djojodibroto, R. D. (2017) Respirologi (Respiratory Medicine). Jakarta: EGC.

Fogel, N. (2015) ‘Tuberculosis: A disease without boundaries’, Tuberculosis, 95(5), pp. 527–531. doi: 10.1016/

Jacobs, A. J. et al. (2016) ‘Antibodies and tuberculosis’, Tuberculosis, 101, pp. 102–113. doi: 10.1016/

Kementerian Kesehatan Republik Indonesia (2019) Hasil Utama Riset Kesehata Dasar (RISKESDAS) tahun 2018 [Chief Results of Basic Health Research (RISKESDAS) in 2018]. Jakarta: Kementerian Kesehatan RI. doi: 10.1088/1751-8113/44/8/085201.

Kementerian Kesehatan RI (2016) Peraturan Menteri Kesehatan Republik Indonesias Tentang Penanggulangan Tuberkulosis. Indonesia.

Kendall, K. and Tao, L. (2013) Sinopsis Organ System Pulmonologi. Jakaarta: Karisma Publishing Group.

Lienhardt, C. et al. (2011) ‘Efficacy and Safety of a 4-Drug Fixed-DoseCombination Regimen Compared withSeparate Drugs for Treatment of Pulmonary Tuberculosis’, Journal American Medical Association, 305(14), pp. 1416–1423. Available at:

Mandell, L. A. and Wunderink, R. (2016) ‘Tuberkulosis’, in Loscalzo, J. (ed.) Harrison Pulmonologi dan Penyakit Kritis. 2nd edn. EGC, pp. 112–134

Patel, P. R. (2020) Lecture Notes Radiology 4th Edition. UK: John Wiley & Sons Ltd.

Rab, T. (2017) Ilmu Penyakit Paru. CV. Trans. Jakarta.

Sitepu, R. et al. (2018) ‘Fixed-dose combination versus separate antituberculosis formulations in pulmonary tuberculosis patients: Evaluation of effectiveness and safety’, International Journal of Applied Pharmaceutics, 10 (Special Issue 1), pp. 208–210. doi: 10.22159/ijap.2018.v10s1.46.

Subuh, M. et al. (2014) Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan RI.

World Health Organization (2016) Global tuberculosis report 2016, WHO.




How to Cite

Duha, K. B., Lestari Ramadhani Nasution, S. ., Girsang, E. ., & Suyono, T. . (2022). Analysis of Efficiency Of KDT-OAT and Removal Preparations on The Recovery of Pulmonary Tuberculosis. International Journal of Health and Pharmaceutical (IJHP), 2(2), 284–289.




Most read articles by the same author(s)

1 2 > >>